Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Drug candidates may fail in clinical trials for many reasons. Biomarker-guided clinical trial design can mitigate the risk of failure and enable more informative clinical experiments regardless of outcomes.
The leading candidate for the repair of the central nervous system in multiple sclerosis failed in a Phase II study, highlighting the complexity ahead for a burgeoning pipeline of academic-led projects.
Less than 6 months after Zika infection was declared a public health emergency, the first clinical trials of DNA vaccines against the virus are beginning.
Jim O'Neill, chair of the United Kingdom's review into antimicrobial resistance, says industry needs to up its game in the battle against antimicrobial resistance.
The standard of care for the treatment of acute myeloid leukaemia (AML) has changed little for decades, but there are now a number of interesting agents in development. This analysis overviews the late-stage AML pipeline and the changing AML market.
The biological rationale for targeting protein–protein interactions as a therapeutic strategy is strong, but identifying viable small-molecule drugs to achieve this has proved highly challenging. This article uses examples of successful discovery efforts to illustrate the research strategies that have proved most useful for different classes of protein–protein interactions.
Anti-inflammatory treatments reduce inflammation but do not necessarily encourage resolution. Here, Fullerton and Gilroy suggest that some chronic inflammatory disorders may be characterized by an inability to resolve inflammation, and discuss the biology of resolution and translational efforts to target it.
Current treatments for chronic kidney disease (CKD) only delay disease progression and can be associated with significant side effects. Here, Suzstak and Breyer discuss emerging novel targets and strategies for the treatment of CKD. Key challenges faced in the development of CKD therapies and future clinical trial designs are considered.
